As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Asia Pacific Vaccine Market: By Technology: Recombinant and Conjugate Vaccine, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Others; By Indication; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments

Asia Pacific Vaccine Market Outlook

The Asia Pacific vaccine market attained a value of about USD 3.92 billion in 2021. The market is further expected to grow in the forecast period of 2022-2027 at a CAGR of 7.8% to reach nearly USD 6.15 billion by 2027.

 

Increasing Availability of Vaccines in the Asia Pacific Region Augmenting the Market Growth

The robust growth of the healthcare sector in the region is propelling the market growth. The emergence of various start-ups and international companies in countries such as China and India are escalating the availability of critical vaccines, which is fuelling the market growth. In addition, the rising affordability and quality of vaccines owing to extensive indigenous manufacturing are significantly contributing to the growth of the industry. The initiation of vaccination drives and campaigns by non-profit and humanitarian organisations is further increasing the demand for vaccines in the region, hence invigorating the industry growth.

 

Asia Pacific Vaccine Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The increasing prevalence of rotavirus outbreaks, especially in developing regions, such as India, Indonesia, and Thailand, among others, are surging the demand for efficient vaccination against the disease. Moreover, governments are increasingly purchasing rotavirus vaccines to ensure free vaccination of children to boost the overall quality of life of their citizens. For instance, the Indian government announced in August 2019 the expansion of coverage of the rotavirus vaccine to end fatality and morbidity associated with the virus by 2022. The initiation of clinical trials by the leading companies to boost the cost-effectiveness of rotavirus vaccines to enable their efficient distribution in low-income countries is providing further impetus to the market growth.

 

Vaccine: Industry Definition and Segmentation

A vaccine is a substance that provides immunity against various contagious diseases. It stimulates the production of antibodies to boost the immune system and prevent the risk or severity of symptoms. It is a crucial preventive and affordable medicine that eliminates the risk of hospitalisation or prolonged illness from various diseases, such as hepatitis, influenzas, and Japanese Encephalitis, among others.

The major technologies of vaccine are:

  • Recombinant and Conjugate Vaccine
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Others

The market can be broadly categorised on the basis of indications into:

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, and Rubella
  • Diphtheria, Pertussis, and Tetanus (DPT)
  • Polio
  • Hepatitis
  • JE (Japanese Encephalitis) Vaccine
  • Others

Based on end uses, the market is divided into:

  • Paediatric Vaccine
  • Adult Vaccine
  • Travellers Vaccine

The EMR report looks into the regional markets of vaccine in the Asia Pacific like China, Japan, India, ASEAN, and Australia, among others.

 

Rising Demand for COVID-19 Vaccines to Bolster the Industry Growth

The surge of the COVID-19 pandemic is fuelling the market growth of vaccine in the region. As countries like India, Indonesia, and Japan, are some of the most affected regions by the pandemic, the demand for rapid COVID-19 vaccination is escalating. The extensive vaccination drive in developed regions, such as Singapore and South Korea, is leading to a surge in demand for COVID-19 vaccines, hence augmenting the market growth. The increasing approvals of the COVID-19 vaccines developed in the region are further bolstering the market growth. In addition, the prioritisation of vaccination by governments in countries like China, Australia, Malaysia, and Hong Kong, among others, to combat mutations of the novel SARS-CoV-2 is expected to drive the growth of the vaccine industry.

The market is poised to witness significant growth owing to increasing research and development (R&D) activities in the region. Moreover, the extensive production of vaccines, along with the presence of several leading companies, in the region, is bolstering the market growth. The introduction of various favourable governments’ initiatives to enhance capabilities in biotechnology is augmenting the market growth. Furthermore, leading companies are increasingly investing in countries such as India and China for the development of novel vaccines owing to the availability of cost-effective raw materials and highly skilled labours, which is providing further impetus to the growth of the market.

 

Key Industry Players in the Asia Pacific Vaccine Market

The report presents a detailed analysis of the following key players in the Asia Pacific vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • CSL Limited
  • Bharat Biotech
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.    
  • AstraZeneca plc.
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical
and Forecast Market Analysis by Segment- Technology, Indication, End Use, Country
Breakup by Technology Recombinant and Conjugate Vaccine, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Others
Breakup by Indication Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal
Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria,
Pertussis, and Tetanus (DPT), Polio, Hepatitis, JE (Japanese Encephalitis) Vaccine, Others
Breakup by End Use Paediatric Vaccine, Adult Vaccine, Travellers Vaccine
Breakup by Country China, India, Japan, ASEAN, Australia, Others
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered CSL Limited, Bharat Biotech, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc., Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Asia Pacific
7    Industry Opportunities and Challenges
8    Asia Pacific Vaccine Market Overview

    8.1    Key Industry Highlights
    8.2    Asia Pacific Vaccine Historical Market (2017-2021) 
    8.3    Asia Pacific Vaccine Market Forecast (2022-2027)
    8.4    Asia Pacific Vaccine Market by Technology
        8.4.1    Recombinant and Conjugate Vaccine
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Inactivated Vaccines
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Live Attenuated Vaccines
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    Toxoid Vaccines
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2017-2021)
            8.4.4.3    Forecast Trend (2022-2027)
        8.4.5    Others
    8.5    Asia Pacific Vaccine Market by Indication
        8.5.1    Pneumococcal Disease
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Influenza
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Human Papilloma Virus
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Meningococcal Disease
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
        8.5.5    Rotavirus
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2017-2021)
            8.5.5.3    Forecast Trend (2022-2027)
        8.5.6    Varicella, Measles, Mumps, and Rubella
            8.5.6.1    Market Share
            8.5.6.2    Historical Trend (2017-2021)
            8.5.6.3    Forecast Trend (2022-2027)
        8.5.7    Diphtheria, Pertussis, and Tetanus (DPT)
            8.5.7.1    Market Share
            8.5.7.2    Historical Trend (2017-2021)
            8.5.7.3    Forecast Trend (2022-2027)
        8.5.8    Polio
            8.5.8.1    Market Share
            8.5.8.2    Historical Trend (2017-2021)
            8.5.8.3    Forecast Trend (2022-2027)
        8.5.9    Hepatitis
            8.5.9.1    Market Share
            8.5.9.2    Historical Trend (2017-2021)
            8.5.9.3    Forecast Trend (2022-2027)
        8.5.10    JE (Japanese Encephalitis) Vaccine
            8.5.10.1    Market Share
            8.5.10.2    Historical Trend (2017-2021)
            8.5.10.3    Forecast Trend (2022-2027)
        8.5.11    Others
    8.6    Asia Pacific Vaccine Market by End Use
        8.6.1    Paediatric Vaccine
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Adult Vaccine
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
        8.6.3    Travellers Vaccine
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2017-2021)
            8.6.3.3    Forecast Trend (2022-2027)
    8.7    Asia Pacific Vaccine Market by Country
        8.7.1    Market Share
            8.7.1.1    China
            8.7.1.2    India
            8.7.1.3    Japan
            8.7.1.4    ASEAN
            8.7.1.5    Australia
            8.7.1.6    Others
9    Regional Analysis
    9.1    China
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
    9.2    India
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
    9.3    Japan
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
    9.4    ASEAN
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
    9.5    Australia
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    CSL Limited
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Bharat Biotech
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    GlaxoSmithKline plc
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Novartis AG
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Pfizer Inc.    
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    AstraZeneca plc.
            12.2.6.1    Company Overview
            12.2.6.2    Product Portfolio
            12.2.6.3    Demographic Reach and Achievements
            12.2.6.4    Certifications
        12.2.7    Others
13    Industry Events and Developments

 

List of Figures and Tables

1.    Asia Pacific Vaccine Market: Key Industry Highlights, 2017 and 2027
2.    Asia Pacific Vaccine Historical Market: Breakup by Technology (USD Billion), 2017-2021
3.    Asia Pacific Vaccine Market Forecast: Breakup by Technology (USD Billion), 2022-2027
4.    Asia Pacific Vaccine Historical Market: Breakup by Indication (USD Billion), 2017-2021
5.    Asia Pacific Vaccine Market Forecast: Breakup by Indication (USD Billion), 2022-2027
6.    Asia Pacific Vaccine Historical Market: Breakup by End Use (USD Billion), 2017-2021
7.    Asia Pacific Vaccine Market Forecast: Breakup by End Use (USD Billion), 2022-2027
8.    Asia Pacific Vaccine Historical Market: Breakup by Country (USD Billion), 2017-2021
9.    Asia Pacific Vaccine Market Forecast: Breakup by Country (USD Billion), 2022-2027
10.    Asia Pacific Vaccine Market Structure

Key Questions Answered in the Report

In 2021, the Asia Pacific vaccine market attained a value of nearly USD 3.92 billion.

The market is projected to grow at a CAGR of 7.8% between 2022 and 2027.

The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach about USD 6.15 billion by 2027.

The market is being aided by the robust growth of the healthcare sector, the rising availability of vaccines, and the introduction of various favourable government initiatives.

The market is expected to be driven by the growing demand for COVID-19 vaccines, the increasing research and development (R&D) activities, and rapid advancements in biotechnology.

The major regions in the industry are China, Japan, India, Australia, and ASEAN, among others.

The major technologies of vaccine in the industry are recombinant and conjugate vaccine, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others.

The significant indications in the market are pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DPT), polio, hepatitis, and JE (Japanese Encephalitis) vaccine, among others.

The various end uses of vaccine are paediatric vaccine, adult vaccine, and travellers vaccine.

The major players in the industry are CSL Limited, Bharat Biotech, GlaxoSmithKline plc, Novartis AG. Pfizer Inc., and AstraZeneca plc., among others.

Analyst Review

The Asia Pacific vaccine market attained a value of nearly USD 3.92 billion in 2021, driven by the robust growth of the healthcare sector. Aided by the increasing research and development (R&D) activities, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 7.8%. The market is projected to reach about USD 6.15 billion by 2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on technologies, the vaccine industry can be segmented into recombinant and conjugate vaccine, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others. By indication, the market is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DPT), polio, hepatitis, and JE (Japanese Encephalitis) vaccine, among others. On the basis of end uses, the industry is divided into paediatric vaccine, adult vaccine, and travellers vaccine. The major regional markets for vaccine are Japan, China, Australia, India, and ASEAN, among others. The key players in the above market include CSL Limited, Bharat Biotech, GlaxoSmithKline plc, Novartis AG. Pfizer Inc., and AstraZeneca plc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER